CONSOLIDATED STATEMENTS OF PREFERRED STOCK (USD $)	36 Months Ended	94 Months Ended
	Mar. 31, 2014	Mar. 31, 2006
Series A Preferred
Beginning Balance, Amount	$ 964,700
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount		964,700
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(964,700)
Ending Balance, Amount		964,700
Series B Preferred
Beginning Balance, Amount	2,651,100
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Amount		2,651,100
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(2,651,100)
Ending Balance, Amount		2,651,100
Series B-1 Preferred
Beginning Balance, Amount	7,523,200
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount		7,523,200
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Amount
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(7,523,200)
Ending Balance, Amount		7,523,200
Series C Preferred
Beginning Balance, Amount	33,958,000
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Amount
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Amount		3,140,800
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount		(25,500)
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount		280,500
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(3,395,800)
Ending Balance, Amount		33,958,000
Preferred Stock
Beginning Balance, Amount	14,534,800
Beginning Balance, Shares	2,884,655
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Amount		964,700
Issuance of Series A preferred stock at $2.302 per share for cash, net of issuance costs of $29,500, Shares		431,930
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Amount		2,651,100
Issuance of Series B preferred stock at $5.545 per share for cash, including conversion of $575,000 face value of 7% convertible notes plus accrued interest of $3,800, net of unamortized discount of $70,800 and issuance costs of $137,000, Shares		515,568
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Amount		7,523,200
Issuance of Series B-1 preferred stock at $5.545 for acquired in-process research and development, Shares		1,356,750
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Amount		3,140,800
Issuance of Series C preferred stock at $6.00 per share for cash, including conversion of $1,655,000 face value of 10% convertible notes plus accrued interest of $408,600, net of unamortized note discount of $13,200 and issuance costs of $47,200, Shares		533,658
Proceeds allocated to warrants issued in connection with Series C preferred stock, Amount		(25,500)
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Amount		280,500
Issuance of Series C preferred stock at $6.00 per share for services and in payment of interest on line of credit, Shares		46,749
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Amount	(14,534,800)
Conversion of all series of preferred stock into VistaGen common stock in connection with the Merger, Shares	(2,884,655)
Ending Balance, Amount		$ 14,534,800
Ending Balance, Shares		2,884,655